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Merkel cell carcinoma (MCC) is an aggressive and lethal skin cancer caused by Merkel cell 
polyomavirus (MCPyV). The presence of CD8+ cytotoxic T cells in these tumors is correlated with 
survival, perhaps because MCPyV oncoproteins expressed in these tumors are targets for the 
immune response. However, only ~20% of patients with MCC have CD8+ T cells present in their 
tumors. In a recent study published in the Journal of Investigative Dermatology, Drs. Olga K. 
Afanasiev (University of Washington) and Paul Nghiem (University of Washington and Clinical 
Research Division) along with an international team of collaborators identify a possible mechanism 
for the low incidence of CD8+ T cells in these tumors. The authors demonstrate that E  -  selectin, a 
molecule involved in CD8+ T cell migration from blood vessels into skin, is downregulated in most 
MCCs, suggesting that current therapies modulating E - selectin expression may be useful in MCC 
treatment. 
For a CD8+ T cell to enter the tumor, it must undergo a process called extravasation. Inflammation 
increases the expression of integrins, such as E - selectin, on cells lining the blood vessel lumen. 
Circulating CD8+ T cells recognize and bind these integrins (adhesion), then migrate out of the blood 
vessel following a chemokine gradient (transmigration). Once they are out of the blood vessel and in 
the tumor itself, CD8+ T cells recognize tumor - specific antigens and mediate a cytotoxic immune 
response. 
Previous studies have demonstrated that squamous cell carcinoma evades the immune response by 
downregulating E - selectin expression (Clark, et al., 2008). To determine if MCC behaves in a 
similar manner Afanasiev et al., stained serial sections of MCC tumors with E - selectin specific 
antibodies, and found a 4 - fold reduction in E - selectin positive blood vessels within the tumor 
periphery compared to surrounding tissue (p < 0.05).  Furthermore, patient survival was positively 
correlated with increased expression of E - selectin within the tumor. Consistent with E - selectin’s 
importance in extravasation, the authors found very low or no CD8+ T cell infiltrate in 75% of the 
MCC they examined. 
Local nitric oxide (NO) production has been shown to downregulate vascular E - selectin (Gehad et 
al., 2012). Afanasiev et al., stained for nitrotyrosine, a byproduct of local NO production, in MCC 
serial sections and found that 43% of tumors had moderate to high nitrotyrosine levels, while in only  
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6% of tumors nitrotyrosine was absent. In addition, nitrotyrosine levels were negatively correlated 
with E - selectin expression in intratumoral blood vessels (p < 0.05). Taken together, these data 
suggest that local production of NO may be one mechanism that MCC downregulates E - selectin 
and excludes CD8+ T cells from the tumor. 
CD8+ T cells have the potential to control tumor progression, and this study identifies one 
mechanism by which MCC may regulate the tumor microenvironment to prevent CD8+ T cells from 
entering the tumor. Importantly, while increased E - selectin is associated with better prognosis for 
patients with MCC, in some other cancers E - selectin is a marker for increased metastatic potential, 
suggesting that drugs which modulate E - selectin levels in blood vessels may be useful only in 
certain tumors, such as MCC. "Therapeutic manipulation of the proposed mechanisms of T cell 
evasion will help establish the causation and clinical relevance of these findings in MCC patients. 
Furthermore, it may be appropriate to combine such treatment with adoptive virus - specific T - cell 
therapy to improve migration of T cells into tumors and thereby augment the efficacy of future 
immune therapy," according to Dr. Afanasiev. 
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Image courtesy of Dr. Olga K. Afanasiev 
Schematic of CD8+ T cell infiltration of Merkel cell 
carcinoma in the presence of E - selectin (top), or the 
exclusion of CD8+ T cells by downregulating E - 
selectin (bottom). 
 
